LB Pharmaceuticals (LBRX) TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit summary

Mechanism and therapeutic profile

• LB-102 is a selective D2, D3, and 5-HT7 inhibitor, designed for improved brain permeability and once-daily dosing compared to amisulpride.

• The drug's bimodal activity allows high doses to suppress dopamine for psychosis and low doses to trigger dopamine release for mood disorders.

• LB-102 aims to treat schizophrenia at 50-100 mg and adjunctive MDD at 15-25 mg, leveraging dose-dependent effects.

Clinical efficacy and safety

• Amisulpride, the parent compound, is highly efficacious with a treatment effect of 0.73 and low discontinuation rates.

• LB-102 demonstrates similar efficacy at much lower doses due to improved potency and brain penetration.

• Phase II trials showed a low rate of extrapyramidal symptoms (EPS) at 5.6% and minimal sedation, suggesting a favorable safety profile.

• Statistically significant improvements were observed in cognition and negative symptoms, with low-dose LB-102 outperforming placebo on the PANSS negative symptom subscale.

Market positioning and differentiation

• LB-102 is positioned to compete on safety, tolerability, and ease of use, with once-daily dosing and minimal food or drug-drug interactions.

• The drug may differentiate itself by addressing residual symptoms and negative symptoms of schizophrenia, where current treatments are lacking.

• Commercial strategy draws lessons from launches of COBENFY and CAPLYTA, focusing on broadening indications to mood disorders.